225 related articles for article (PubMed ID: 28733186)
1. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.
Luft T; Benner A; Jodele S; Dandoy CE; Storb R; Gooley T; Sandmaier BM; Becker N; Radujkovic A; Dreger P; Penack O
Lancet Haematol; 2017 Sep; 4(9):e414-e423. PubMed ID: 28733186
[TBL] [Abstract][Full Text] [Related]
2. Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation.
Pedraza A; Salas MQ; Rodríguez-Lobato LG; Escribano-Serrat S; Suárez-Lledo M; Martínez-Cebrian N; Solano MT; Arcarons J; Rosiñol L; Gutiérrez-García G; Fernández-Avilés F; Moreno-Castaño AB; Molina P; Pino M; Carreras E; Díaz-Ricart M; Rovira M; Palomo M; Martínez C
Transplant Cell Ther; 2024 Feb; 30(2):187.e1-187.e12. PubMed ID: 38000709
[TBL] [Abstract][Full Text] [Related]
3. Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation.
Varma A; Rondon G; Srour SA; Chen J; Ledesma C; Champlin RE; Ciurea SO; Saliba RM
Biol Blood Marrow Transplant; 2020 May; 26(5):1013-1020. PubMed ID: 32045652
[TBL] [Abstract][Full Text] [Related]
4. EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation.
Sanchez-Escamilla M; Flynn J; Devlin S; Maloy M; Fatmi SA; Tomas AA; Escribano-Serrat S; Ponce D; Sauter CS; Giralt SA; Scordo M; Perales MA
Bone Marrow Transplant; 2023 May; 58(5):498-505. PubMed ID: 36721042
[TBL] [Abstract][Full Text] [Related]
5. EASIX and mortality after allogeneic stem cell transplantation.
Luft T; Benner A; Terzer T; Jodele S; Dandoy CE; Storb R; Kordelas L; Beelen D; Gooley T; Sandmaier BM; Sorror M; Zeisbrich M; Radujkovic A; Dreger P; Penack O
Bone Marrow Transplant; 2020 Mar; 55(3):553-561. PubMed ID: 31558788
[TBL] [Abstract][Full Text] [Related]
6. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation.
Nawas MT; Sanchez-Escamilla M; Devlin SM; Maloy MA; Ruiz JD; Sauter CS; Giralt SA; Perales MA; Scordo M
Blood Adv; 2022 Nov; 6(22):5898-5907. PubMed ID: 35977079
[TBL] [Abstract][Full Text] [Related]
7. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
[TBL] [Abstract][Full Text] [Related]
8. EASIX for prediction of survival in lower-risk myelodysplastic syndromes.
Merz A; Germing U; Kobbe G; Kaivers J; Jauch A; Radujkovic A; Hummel M; Benner A; Merz M; Dreger P; Luft T
Blood Cancer J; 2019 Nov; 9(11):85. PubMed ID: 31712595
[TBL] [Abstract][Full Text] [Related]
9. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
10. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
11. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Kennedy GA; Varelias A; Vuckovic S; Le Texier L; Gartlan KH; Zhang P; Thomas G; Anderson L; Boyle G; Cloonan N; Leach J; Sturgeon E; Avery J; Olver SD; Lor M; Misra AK; Hutchins C; Morton AJ; Durrant ST; Subramoniapillai E; Butler JP; Curley CI; MacDonald KPA; Tey SK; Hill GR
Lancet Oncol; 2014 Dec; 15(13):1451-1459. PubMed ID: 25456364
[TBL] [Abstract][Full Text] [Related]
12. Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation.
Peña M; Salas MQ; Mussetti A; Moreno-Gonzalez G; Bosch A; Patiño B; Jiménez L; Kara M; Parody R; Sureda A
Blood Adv; 2021 Sep; 5(17):3418-3426. PubMed ID: 34495311
[TBL] [Abstract][Full Text] [Related]
13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
14. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study.
Penack O; Luft T; Peczynski C; Benner A; Sica S; Arat M; Itäla-Remes M; Corral LL; Schaap NPM; Karas M; Raida L; Schroeder T; Dreger P; Metafuni E; Ozcelik T; Sandmaier BM; Kordelas L; Moiseev I; Schoemans H; Koenecke C; Basak GW; Peric Z
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38199608
[TBL] [Abstract][Full Text] [Related]
15. EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.
Luft T; Wendtner CM; Kosely F; Radujkovic A; Benner A; Korell F; Kihm L; Bauer MF; Dreger P; Merle U
Front Immunol; 2021; 12():634416. PubMed ID: 34248931
[TBL] [Abstract][Full Text] [Related]
16. Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.
Song GY; Jung SH; Kim K; Kim SJ; Yoon SE; Lee HS; Kim M; Ahn SY; Ahn JS; Yang DH; Kim HJ; Lee JJ
BMC Cancer; 2020 Aug; 20(1):803. PubMed ID: 32831058
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
Finke J; Schmoor C; Bethge WA; Ottinger H; Stelljes M; Volin L; Heim D; Bertz H; Grishina O; Socie G
Lancet Haematol; 2017 Jun; 4(6):e293-e301. PubMed ID: 28583289
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
